BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma

Rok, strany: 2017, 626 - 632

BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma. However, their role in acral and mucosal melanoma remains unclear. Records were reviewed of patients with metastatic or unresectable BRAF-mutant acral and mucosal melanoma hospitalized and administrated BRAF inhibitors during January 2011 and March 2016. Clinical data were collected to determine PFS, ORR, DCR, OS, and safety. Among 28 acral and 12 mucosal melanoma patients treated with BRAF inhibitors, median PFS were 3.6 (95%CI 3.0-6.4) and 4.4 (95%CI 0.8-12.7) months, median OS were 6.2 (95%CI 6.1-12.1) and 8.2 (95%CI 6.6-19.9) months; ORRs were 38.1% and 20.0%, DCRs were 81.0% and 70.0% in acral and mucosal melanoma, respectively. BRAF inhibitors were well tolerated. The most common adverse effects (AEs) were cutaneous and hematological. Grade 3/4 AEs were relatively rare. In conclusion, BRAF inhibitors have acceptable efficacy and good tolerance in BRAF mutant acral and mucosal melanoma. Keywords: BRAF inhibitor, acral, mucosal, melanoma

ISO 690:

Bai, X., Mao, L., Chi, Z., Sheng, X., Cui, C., Kong, Y., Dai, J., Wang, X., Li, S., Tang, B., Lian, B., Zhou, L., Yan, X., Guo, J., Si, L. 2017. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. In NEOPLASMA, vol. 64, no.4, pp. 626-632. 0028-2685.

APA:

Bai, X., Mao, L., Chi, Z., Sheng, X., Cui, C., Kong, Y., Dai, J., Wang, X., Li, S., Tang, B., Lian, B., Zhou, L., Yan, X., Guo, J., Si, L. (2017). BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. NEOPLASMA, 64(4), 626-632. 0028-2685.